| Autor: |
Schaaf ZA; Department of Urologic Surgery, University of California Davis, Sacramento, CA 95817, USA., Ning S; Department of Urologic Surgery, University of California Davis, Sacramento, CA 95817, USA., Leslie AR; Department of Urologic Surgery, University of California Davis, Sacramento, CA 95817, USA., Sharifi M; Department of Urologic Surgery, University of California Davis, Sacramento, CA 95817, USA., Han X; Department of Urologic Surgery, University of California Davis, Sacramento, CA 95817, USA., Armstrong C; Department of Urologic Surgery, University of California Davis, Sacramento, CA 95817, USA., Lou W; Department of Urologic Surgery, University of California Davis, Sacramento, CA 95817, USA., Lombard AP; Department of Urologic Surgery, University of California Davis, Sacramento, CA 95817, USA.; UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA 95817, USA.; Department of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA 95616, USA., Liu C; Department of Urologic Surgery, University of California Davis, Sacramento, CA 95817, USA.; UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA 95817, USA., Gao AC; Department of Urologic Surgery, University of California Davis, Sacramento, CA 95817, USA.; UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA 95817, USA.; VA Northern California Health Care System, Sacramento, CA 95655, USA. |
| Abstrakt: |
Current common treatments for castration-resistant prostate cancer (CRPC) typically belong to one of three major categories: next-generation anti-androgen therapies (NGAT) including enzalutamide, abiraterone acetate, apalutamide, and darolutamide; taxane therapy represented by docetaxel; and PARP inhibitors (PARPi) like olaparib. Although these treatments have shown efficacy and have improved outcomes for many patients, some do not survive due to the emergence of therapeutic resistance. The clinical landscape is further complicated by limited knowledge about how the sequence of treatments impacts the development of therapeutic cross-resistance in CRPC. We have developed multiple CRPC models of acquired therapeutic resistance cell sublines from C4-2B cells. These include C4-2B MDVR, C4-2B AbiR, C4-2B ApaR, C4-2B DaroR, TaxR, and 2B-olapR, which are resistant to enzalutamide, abiraterone, apalutamide, darolutamide, docetaxel, and olaparib, respectively. These models are instrumental for analyzing gene expression and assessing responses to various treatments. Our findings reveal distinct cross-resistance characteristics among NGAT-resistant cell sublines. Specifically, resistance to enzalutamide induces resistance to abiraterone and vice versa, while maintaining sensitivity to taxanes and olaparib. Conversely, cells with acquired resistance to docetaxel exhibit cross-resistance to both cabazitaxel and olaparib but retain sensitivity to NGATs like enzalutamide and abiraterone. OlapR cells, significantly resistant to olaparib compared to parental cells, are still responsive to NGATs and docetaxel. Moreover, OlapR models display cross-resistance to other clinically relevant PARP inhibitors, including rucaparib, niraparib, and talazoparib. RNA-sequencing analyses have revealed a complex network of altered gene expressions that influence signaling pathways, energy metabolism, and apoptotic signaling, pivotal to cancer's evolution and progression. The data indicate that resistance mechanisms are distinct among different drug classes. Notably, NGAT-resistant sublines exhibited a significant downregulation of androgen-regulated genes, contrasting to the stable expression noted in olaparib and docetaxel-resistant sublines. These results may have clinical implications by showing that treatments of one class can be sequenced with those from another class, but caution should be taken when sequencing drugs of the same class. |
